Together, these data demonstrate that Mpzl3 inhibition is a potential therapeutic approach for treatment of obesity and related comorbid conditions, including insulin resistance, hyperlipidemia and cardiovascular dysfunction. Here, MPZL3 is linked to hyperlipidemia.